← Back to Search

Prostaglandin Analog

Topical Bimatoprost in the Treatment of Migraine

Phase 2
Waitlist Available
Research Sponsored by Manistee Partners
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Diagnosis of migraines based on International Classification of Headache Disorders (ICHD) II criteria and experiencing headaches for 4 or more days per month.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved

Summary

This trial is testing if a skin-applied medication called bimatoprost can help people who suffer from migraines by reducing their headache symptoms and improving their quality of life.

Eligible Conditions
  • Migraine
  • Chronic Headaches
  • Headache Disorders

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Reduction in Headache Frequency
Secondary study objectives
Duration of Headaches
Intensity of Headaches
Migraine Disability Assessment Scale (MIDAS)--Quality of Life

Side effects data

From 2016 Phase 4 trial • 379 Patients • NCT02017327
1%
myocardial infarction
1%
hypotension
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lumigan 0.01%
Monoprost
Lumigan 0.03% Unit Dose

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Bimatoprost Topical SolutionExperimental Treatment1 Intervention
0.03% bimatoprost topical solution applied daily to the nail bed of fingers on one hand for 12 weeks
Group II: ControlPlacebo Group1 Intervention
Saline placebo topically applied daily to the nail be of fingers on one hand for 12 weeks

Find a Location

Who is running the clinical trial?

Manistee PartnersLead Sponsor
Robert L Bratzler, PhDStudy ChairManistee Partners
~9 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top